Special drug-use survey of Tarlige (evaluation of the efficacy in patients with peripheral neuropathic pain)

DAIICHI SANKYO CO., LTD0 个研究点目标入组 1,890 人开始时间: 2019年10月15日最近更新: 2024年4月1日

试验速览

暂无简介。

•1.Patients with peripheral neuropathic pain not treated with Tarlige tablet before
•2.Patients with 12 or more points in the neuropathic pain screening questionnaire
•3.Patients with pain lasting more than 3 months
•4.Patients with a pain scale of 40 mm or more on VAS before administration of Tarlige tablet
•5.Patients who started administration of Tarlige tablet during the contract period (contract period based on the contract with each medical site)
•6.Patients who started administration of Tarlige tablet during the registration period
•7.Patients from whom written informed consent was obtained

•1.Patients with a pain scale of 90 mm or less on VAS before administration of Tarlige tablet
•2.Patients with other pain unrelated to PNP, that may confound the assessment of PNP
•3.Patients with Neurologic disorders (depression, bipolar disorder, schizophrenia, etc.)
•4.Patients with dementia, etc. who cannot respond appropriately to questionnaires and VAS for pain

发起方

DAIICHI SANKYO CO., LTD